These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37081961)

  • 21. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
    Liu L; Chen J; Wang L; Chen C; Chen L
    Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system.
    Chinzowu T; Chyou TY; Nishtala PS
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1190-1198. PubMed ID: 35670078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs.
    Klaewsongkram J; Sukasem C; Thantiworasit P; Suthumchai N; Rerknimitr P; Tuchinda P; Chularojanamontri L; Srinoulprasert Y; Rerkpattanapipat T; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Tovanabutra N; Srisuttiyakorn C;
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):219-227.e4. PubMed ID: 29800753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
    Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
    Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
    Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
    Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Mazhar F; Pozzi M; Gentili M; Scatigna M; Clementi E; Radice S; Carnovale C
    CNS Drugs; 2019 Jun; 33(6):581-592. PubMed ID: 30977109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.
    Sato T; Cheng CL; Park HW; Kao Yang YH; Yang MS; Fujita M; Kumagai Y; Tohkin M; Saito Y; Sai K
    Clin Transl Sci; 2021 May; 14(3):1002-1014. PubMed ID: 33382928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dermatologic toxicities in epidermal growth factor receptor: a comprehensive pharmacovigilance study from 2013 to 2023.
    Dan H; Jiang Q; Jia X; Qi G; Zong D; Li Z
    Front Med (Lausanne); 2023; 10():1283807. PubMed ID: 38327269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe cutaneous adverse reactions associated with systemic ivermectin: A pharmacovigilance analysis.
    Bomze D; Sprecher E; Geller S
    J Dermatol; 2022 Aug; 49(8):769-774. PubMed ID: 35475524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization.
    Zheng Y; Zhou W; Guo X; Chi L; Chen C; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
    Expert Opin Drug Saf; 2022 Aug; 21(8):1127-1133. PubMed ID: 35196201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
    Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
    Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
    Wang Y; Cui C; Ren X; Dong X; Cui W
    Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allopurinol-induced severe cutaneous adverse drug reactions: Risk minimization measures in Malaysia.
    Panickar R; Wo WK; Ali NM; Tang MM; Ramanathan GRL; Kamarulzaman A; Aziz Z
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1254-1262. PubMed ID: 33084196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.